Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This WeekThe Motley Fool • 07/08/22
Crispr Therapeutics: Innovation Day Showcases Upside Opportunities In Short And Long TermSeeking Alpha • 06/23/22
CRISPR Therapeutics AG (CRSP) Management Presents at Innovation Day Conference (Transcript)Seeking Alpha • 06/22/22
CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?Zacks Investment Research • 06/20/22
CRISPR Therapeutics AG (CRSP) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/15/22
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, ImpressiveBenzinga • 06/13/22
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) CongressGlobeNewsWire • 06/11/22
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) CongressBusiness Wire • 06/11/22